Is Amarin a Buy or Sell in the Aftermath of Jenkin’s Rejection?

I always buy on irrational pullbacks.


 

If you were here on August 31st, you knew not to hold onto Amarin shares any longer.  Simply click on the “Free Content” tab and then on Amarin (AMRN) and you’ll clearly see an inauspicious omen in the investor sector of the “Present” container.  Here’s a look at the 3-Month Chart.

3-Month Chart

You’ll note that the 31.5% run-up began with my article in Seeking Alpha published July 21st and ended with this press release dated yesterday, September 12th.

Press Release

Not only did I predict the ultimate outcome of the SPA rescission appeal, but I gave you a look ahead into Q4 which will feature two distinctly different realities for investors and corporate leadership.

John Thero will continue to decry the injustice of Amarin’s regulatory predicament, but investors will move on with a clear vision of the future.  It is for this reason that I purchased 1,480 shares at $1.41 today.  And I expect to make a healthy return of 15% or more by November 15th.

Vascepa sales will climb steeply in the fall months ahead giving the company a new vision of a prosperous future.  Meanwhile, John Thero will make no small amount of noise on the judicial front which will cause investors to once again feel confident and buy in.

Always be well.

November 21, 2014 – I think it’s safe to say my analysis was amiss here.  The stock sunk to a low of $0.79, far below what I’d anticipated.  John Thero has been strangely silent regarding the issue of fair treatment by the FDA, foregoing further appeals of the SPA rescission.  Prescriptions have steadily risen and there has also been a wealth of good scientific news.  The stock has recovered a bit.  I’m still %0.10 underwater and it remains to be seen what’s next.

Though I won’t be buying more (don’t have the funds as it’s Christmas after all) I am curious as to what this silence means.  I’ll be doing a new reading on Amarin and posting it soon.